Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06678672 · ClinicalTrials.gov registry record · NA

Contingency Management for Veteran Smokers Undergoing Major Elective Surgery

A NA study of Tobacco Use Disorder and Substance Use Disorder (SUD), sponsored by University of California, San Francisco.

Recruiting
Registry status
NA
Development phase
36
Enrollment target
1
Study location

NCT06678672: Recruiting NA study of Tobacco Use Disorder and Substance Use Disorder (SUD), sponsored by University of California, San Francisco.

NCT06678672 is a NA study of Tobacco Use Disorder and Substance Use Disorder (SUD) that is actively recruiting participants, run by University of California, San Francisco. The registered enrollment target is 36 participants, below the 239-participant average among 70 other Tobacco Use Disorder trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06678672, a NA study of Tobacco Use Disorder and Substance Use Disorder (SUD), is actively recruiting participants, sponsored by University of California, San Francisco.

RECRUITING
Registry status
NA
Development phase
36 participants
Enrollment target
1
Study location

Study Summary

The goal of this study is to design and test the first mobile contingency management (CM) smoking cessation intervention for military Veterans undergoing major elective surgery. Smoking is the leading risk factor for postoperative complications and is associated with longer hospital stays, reoperations, and 30-day mortality. Smoking rates among patients undergoing major elective surgery are high, 22.3-43.0%. It is imperative to identify efficacious, strategically timed smoking cessation interventions for surgery patients. CM incentivizes smoking cessation through positive reinforcement (rewards) when bioverified abstinence is achieved. To ensure feasibility, CM must be tailored to the clinical context. CM for smoking cessation has never been delivered before and after major surgery, nor has mobile CM bioverification been trialed perioperatively. The investigators will develop and test a tailored mobile smoking cessation CM protocol for Veterans undergoing major elective surgery.

Primary Outcome

Ability to recruit ≥70% of the target sample within the study timeline, i.e., at least 25 of 36 participants are enrolled.

Conditions Studied

Tobacco Use Disorder Substance Use Disorder (SUD)

Interventions

  • BEHAVIORAL Treatment as Usual (TAU)
  • BEHAVIORAL Contingency Management (CM)

Study Locations (1)

California

  • San Francisco VA Health Care System - San Francisco

Trial Details

FieldValue
Enrollment Target 36 participants
Start Date 2025-08-01
Est. Completion 2026-07-01
Phase NA
University of California, San Francisco

1,713 total trials

What NCT06678672 shows while recruiting

NCT06678672 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 239-participant average among 70 other Tobacco Use Disorder trials with a reported enrollment target (85% lower).

The record links to 2 conditions, with Tobacco Use Disorder appearing as the primary indexed condition, and to 2 interventions - of which Treatment as Usual (TAU) is the first listed.

NCT06678672 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT06678672 about?

NCT06678672 is a clinical study titled "Contingency Management for Veteran Smokers Undergoing Major Elective Surgery". The goal of this study is to design and test the first mobile contingency management (CM) smoking cessation intervention for military Veterans undergoing major elective surgery. Smoking is the leading risk factor for postoperative complications and is associated with longer hospital stays, reoperati...

What is the current status of trial NCT06678672?

This trial is currently recruiting. It is a NA study. The enrollment target is 36 participants. The study started on 2025-08-01. Estimated completion is 2026-07-01.

What conditions does trial NCT06678672 study?

This clinical trial studies the following conditions: Tobacco Use Disorder, Substance Use Disorder (SUD).

What interventions are being tested in trial NCT06678672?

The interventions under investigation include: Treatment as Usual (TAU) (BEHAVIORAL), Contingency Management (CM) (BEHAVIORAL).

Who is sponsoring clinical trial NCT06678672?

This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06678672 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Tobacco Use Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06678672's enrollment target sits among peer trials

36 60th of 70 higher than 11 of 70 other Tobacco Use Disorder trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Tobacco Use Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00929006 · 36 participants · Early Phase 1

    Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism

  • NCT01891318 · 36 participants · Phase 1

    Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study

  • NCT02291848 · 36 participants · Phase 1

    Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma

  • NCT02366819 · 36 participants · Phase 4

    Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06678672

Source: ClinicalTrials.gov NCT06678672, the US trial registry maintained by the National Library of Medicine. NCT06678672 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.